Skip to content

Zymeworks ZYME Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Amgen logo
AmgenAMGN
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
Charles River Laboratories logo
Charles River LaboratoriesCRL
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's common stock, par value (in dollars per share)?
Zymeworks (ZYME) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has Zymeworks's common stock, par value (in dollars per share) changed year-over-year?
Zymeworks's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Zymeworks's common stock, par value (in dollars per share)?
Over 3 years (2022 to 2025), Zymeworks's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.